# Adrenomed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adrenomed

- Industry: Biotechnology
- Headquarters: Hennigsdorf, Germany
- Website: www.adrenomed.com
- Total disclosed funding: $60M
- Latest round: Series E (Nov 25, 2020)
- Investors on record: 2

## About

Adrenomed AG is a clinical-stage biopharmaceutical company focused on developing innovative therapies to restore vascular integrity in critically ill patients, primarily targeting conditions like septic shock.Founded in 2009, Adrenomed AG is based in Hennigsdorf, Germany. The company specializes in developing monoclonal antibodies, with its lead product being Enibarcimab, aimed at addressing severe vascular complications. The firm has secured a total funding of EUR 22.000 mn through various investment rounds, the most recent being a Venture Debt round in July 2022 where they raised EUR 2.5 million from HBM Partners. Jens Schneider-Mergener and Richard Jones serve as the company's CEOs.Adrenomed AG specializes in developing innovative biopharmaceuticals aimed at restoring vascular integrity in critically ill patients. Its core product, Enibarcimab (formerly known as Adrecizumab), is a first-in-class monoclonal antibody designed to target the vasoprotective peptide Adrenomedullin. This treatment addresses life-threatening conditions such as septic shock, where loss of vascular integrity leads to severe complications including increased vascular leakage and organ dysfunction. By leveraging a biomarker-guided approach using two specific biomarkers—bio-ADM and DPP3—Adrenomed enables healthcare providers to identify patients who are most likely to benefit from therapy with Enibarcimab. The company’s products are currently being developed and evaluated primarily in European markets, including Belgium, France, Germany, and the Netherlands.Adrenomed AG operates within a clinical-stage biopharmaceutical model, focusing on partnerships with healthcare institutions and clinical trial networks to advance its product development. The company generates revenue through strategic collaborations and potentially through the future commercialization of Enibarcimab, which is currently undergoing pivotal clinical trials including a Phase II proof-of-concept study. In this model, transactions typically involve agreements with hospitals and research institutions for the clinical deployment of their products, as well as licensing agreements for potential future sales. Pricing structures for these products will be determined as they progress toward market approval, with revenue anticipated to arise from direct sales to healthcare providers once Enibarcimab is approved for use.In July 2022, Adrenomed AG raised EUR 2.5 million in venture debt funding, which will support the ongoing development of Enibarcimab and advance clinical trials. The company aims to expand its product offerings and enter new markets, with a focus on regions such as Belgium, France, Germany, and the Netherlands, where it currently evaluates its products. The strategic plan includes leveraging funding to enhance clinical engagements and potentially broaden collaborations with healthcare institutions to facilitate the successful commercialization of its therapies.

## Funding rounds

- Series E, Nov 25, 2020, $26M — Wellington Partners, HBM Partners
- Series D, May 6, 2020, $1.5M — HBM Partners
- Series D, Oct 12, 2019, $1.7M — HBM Partners
- Series D, May 24, 2019, $3.5M — HBM Partners
- Series D, Nov 26, 2018, $27M — Wellington Partners, HBM Partners

## Investors

- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series D, Series E
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series D, Series E